Peer-reviewedCC BY-NCClinical Pediatric Hematology-Oncology30 Oct 2026

Paediatric Sickle Cell Disease in Nigeria: From Burden Characterisation to Bridging the Implementation Gap – A Critical Policy Review

Yusuf Yakub Oloriegbe¹
Bello Abdullahi Ibrahim¹
Maimuna Orahachi Yusuf¹
Dalhat Saliu Afegbua¹
Tijjani Umara²

¹Department of Paediatrics, Faculty of Clinical Sciences, Federal University of Health Sciences, Azare, Bauchi State, Nigeria
²Department of Paediatrics, Federal University of Health Sciences Teaching Hospital, Azare, Bauchi State, Nigeria

Abstract

Background : Nigeria bears the world’s highest burden of sickle cell disease (SCD), with approximately 150,000 affected infants born annually, yet outcomes remain poor. This review synthesises evidence on epidemiology, clinical phenotype, treatment gaps, and mortality to inform implementation priorities. Methods : We reviewed published literature from January 2000 to May 2026 on Nigerian paediatric SCD, extracting data on prevalence, clinical complications, intervention coverage, and survival. Implementation barriers were mapped using the Consolidated Framework for Implementation Research (CFIR). Results : National pooled prevalence is 4.0%, reaching 7.0% in the North-West, with SCD accounting for 10.0% of paediatric admissions across 10 tertiary healthcare facilities (range, 2.1%-16.3%). The phenotype is severe and early-onset, characterised by vaso-occlusive crises (66-81%), severe bacterial infections (24-32%), and acute chest syndrome (11-27%). Access to key interventions remains limited: hydroxyurea coverage is approximately 13%, penicillin prophylaxis is prescribed by fewer than 40% of paediatricians, and transcranial Doppler screening is available in only 3 of 18 specialised clinics. CFIR identified infrastructure deficits, out-of-pocket costs, weak policy implementation, and clinician hesitancy as major barriers. Conclusion : Closing the implementation gap, rather than further characterising disease burden, is the urgent priority for improving SCD outcomes in Nigeria.

Critical gaps in infectious disease prevention and control: insights from IHR-2005 implementation enablers and challenges at key entry points in Bangladesh
Goutam Kumar Dutta, Md. Khaledul Hasan, Kazi Istiaque Sanin +9
BMC Public Health30 Sep 2026Peer-reviewedCC BY-NC-ND 4.0Epidemiology & public healthCrossref
Clinical and multi-omics characterisation of early neurodevelopmental disorders associated with critical congenital heart disease: the prospective cohort CATAMARAN neonatal study protocol
Oscar Werner, Véronique Ferchaud-Roucher, Matilde Karakachoff +34
BMJ Open8 Sep 2026Peer-reviewedCC BYFull textEpidemiology & public healthHAL
Implementation science in global paediatric oncology: a scoping review protocol.
Laura van Tinteren, Larissa Klootwijk, Caitlyn Duffy +16
BMJ open20 Oct 2026Peer-reviewedCC BY-NCFull textGeneral medicineEurope PMCCrossref
Bridging the Artificial Intelligence Translation Gap in Perioperative Pulmonary and Respiratory Complications: A Practical Framework for Institution-Level Implementation
Ji-Yeon Lee, Yong-Ho In, Jong-Ho Kim +3
Diagnostics (Basel, Switzerland)23 Sep 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Implementation and Performance of a Clinical Debriefing Programme in a Paediatric Emergency Department: A Descriptive Qualitative Review
Katie Leanne Reeves, Amelia Batty, Karin Plummer
Emergency Medicine Australasia28 Oct 2026Peer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC

Cite

BibTeX RIS

BibTeX

@article{oloriegbe2026paediatric,
  title = {{Paediatric Sickle Cell Disease in Nigeria: From Burden Characterisation to Bridging the Implementation Gap – A Critical Policy Review}},
  author = {Yusuf Yakub Oloriegbe and Bello Abdullahi Ibrahim and Maimuna Orahachi Yusuf and Dalhat Saliu Afegbua and Tijjani Umara},
  journal = {Clinical Pediatric Hematology-Oncology},
  year = {2026},
  month = oct,
  doi = {10.15264/cpho.2026.33.2.61},
  url = {https://doi.org/10.15264/cpho.2026.33.2.61},
  note = {CC BY-NC},
}

RIS

TY  - JOUR
TI  - Paediatric Sickle Cell Disease in Nigeria: From Burden Characterisation to Bridging the Implementation Gap – A Critical Policy Review
AU  - Yusuf Yakub Oloriegbe
AU  - Bello Abdullahi Ibrahim
AU  - Maimuna Orahachi Yusuf
AU  - Dalhat Saliu Afegbua
AU  - Tijjani Umara
PY  - 2026
DA  - 2026/10/30
JO  - Clinical Pediatric Hematology-Oncology
DO  - 10.15264/cpho.2026.33.2.61
UR  - https://doi.org/10.15264/cpho.2026.33.2.61
AB  - Background : Nigeria bears the world’s highest burden of sickle cell disease (SCD), with approximately 150,000 affected infants born annually, yet outcomes remain poor. This review synthesises evidence on epidemiology, clinical phenotype, treatment gaps, and mortality to inform implementation priorities. Methods : We reviewed published literature from January 2000 to May 2026 on Nigerian paediatric SCD, extracting data on prevalence, clinical complications, intervention coverage, and survival. Implementation barriers were mapped using the Consolidated Framework for Implementation Research (CFIR). Results : National pooled prevalence is 4.0%, reaching 7.0% in the North-West, with SCD accounting for 10.0% of paediatric admissions across 10 tertiary healthcare facilities (range, 2.1%-16.3%). The phenotype is severe and early-onset, characterised by vaso-occlusive crises (66-81%), severe bacterial infections (24-32%), and acute chest syndrome (11-27%). Access to key interventions remains limited: hydroxyurea coverage is approximately 13%, penicillin prophylaxis is prescribed by fewer than 40% of paediatricians, and transcranial Doppler screening is available in only 3 of 18 specialised clinics. CFIR identified infrastructure deficits, out-of-pocket costs, weak policy implementation, and clinician hesitancy as major barriers. Conclusion : Closing the implementation gap, rather than further characterising disease burden, is the urgent priority for improving SCD outcomes in Nigeria.
SN  - 2233-5250
SN  - 2233-4580
ER  -